- Home
- AII vs ABEO Comparison
AII vs ABEO Comparison
Compare AII & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AII
- ABEO
- Stock Information
- Founded
- AII 2006
- ABEO 1974
- Country
- AII United States
- ABEO United States
- Employees
- AII N/A
- ABEO N/A
- Industry
- AII Property-Casualty Insurers
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- AII Finance
- ABEO Health Care
- Exchange
- AII Nasdaq
- ABEO Nasdaq
- Market Cap
- AII 370.5M
- ABEO 332.0M
- IPO Year
- AII 2025
- ABEO 1980
- Fundamental
- Price
- AII $19.96
- ABEO $6.83
- Analyst Decision
- AII Buy
- ABEO Strong Buy
- Analyst Count
- AII 4
- ABEO 6
- Target Price
- AII $21.67
- ABEO $18.17
- AVG Volume (30 Days)
- AII 78.8K
- ABEO 702.3K
- Earning Date
- AII 08-12-2025
- ABEO 08-14-2025
- Dividend Yield
- AII N/A
- ABEO N/A
- EPS Growth
- AII N/A
- ABEO N/A
- EPS
- AII 60.71
- ABEO 0.99
- Revenue
- AII $260,047,000.00
- ABEO $400,000.00
- Revenue This Year
- AII $25.82
- ABEO N/A
- Revenue Next Year
- AII $25.78
- ABEO $339.63
- P/E Ratio
- AII $0.33
- ABEO $6.91
- Revenue Growth
- AII 1.73
- ABEO N/A
- 52 Week Low
- AII $15.78
- ABEO $3.93
- 52 Week High
- AII $20.32
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- AII N/A
- ABEO 52.71
- Support Level
- AII N/A
- ABEO $6.70
- Resistance Level
- AII N/A
- ABEO $7.15
- Average True Range (ATR)
- AII 0.00
- ABEO 0.31
- MACD
- AII 0.00
- ABEO -0.02
- Stochastic Oscillator
- AII 0.00
- ABEO 46.62
About AII American Integrity Insurance Group Inc. Common Stock
American Integrity Insurance Group Inc is engaged in the property and casualty insurance business. It provides personal residential property insurance for single-family homeowners and condominium owners as well as coverage for vacant dwellings and investment properties, predominantly in Florida. The Company's property and casualty insurance is currently offered in Florida, South Carolina, and Georgia.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.